Hemosonics-Hero-mobile-blood-dials

Company News

HemoSonics Wins Medical Device Network Excellence Award in Two Categories

HemoSonics wins in product launch and business expansion categories as more hospitals adopt its Quantra® Hemostasis System for acute bleeding management.DURHAM, N.C., Oct. 5, 2023 /PRNewswire/ — HemoSonics, a medical device company delivering individualized diagnostic solutions for acute care bleeding and the management of coagulation, announced today that the company has won in both the […]

Read More

HemoSonics Receives Vizient Innovative Technology Contract for Quantra Hemostasis System

Contract awarded for products that bring improvement to the healthcare industry; HemoSonics’ Quantra Hemostasis System provides comprehensive whole blood coagulation analysis at the point of care in less than 15 minutes. DURHAM, N.C. – August 3, 2023 – HemoSonics®, a medical device technology company focused on acute bleeding management, today announced its Quantra® Hemostasis System […]

Read More

HEMOSONICS AWARDED FDA 510(k) CLEARANCE FOR QUANTRA® HEMOSTASIS SYSTEM WITH QSTAT® CARTRIDGE

Next-Generation point-of-care whole blood hemostasis system now covers the broadest range of clinical indications in the U.S. to date. Durham, North Carolina – November, 30, 2022 – HemoSonics, LLC, a leading medical device company delivering individualized diagnostic solutions for Patient Blood Management (PBM), announced today that it has received 510(k) market clearance from the U.S. […]

Read More

HEMOSONICS APPOINTS DR. BRUCE SPIESS AS MEDICAL DIRECTOR AND EXHIBITS DIAGNOSTIC SOLUTIONS AT ANESTHESIOLOGY®, THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS (ASA) ANNUAL MEETING

Newly appointed Medical Director, Bruce Spiess, MD, FAHA to moderate the educational session “Listening to the Blood: An Update on the Quantra® System, the Latest Technology in the Management of Critical Bleeding” Clinical tools on display to provide actionable information to guide the management of critical bleeding enabling clinicians to choose the right treatment in […]

Read More

HemoSonics Welcomes FDA Support of Viscoelastic Coagulation Analyzers for COVID-19 Patients; Highlights the Benefits of the Quantra® Hemostasis Analyzer

Charlottesville, VA, January 19, 2021 – HemoSonics welcomes the January 14th guidance of the US Food and Drug Administration (FDA) that broadens the use of viscoelastic coagulation analyzers for hospital patient healthcare settings in response to COVID-19. The FDA guidance is intended, for the duration of the COVID-19 public health emergency, to expand the availability […]

Read More

HemoSonics Adds Remote Viewer to its Quantra® QPlus® System, Bringing Rapid Results to Clinicians Anywhere in the Hospital

Charlottesville, VA – September 10, 2020 – HemoSonics announced today that its Quantra Desktop Remote Viewer Software (QDRV) has received a 510(k) clearance from the FDA. The QDRV enables remote access to its flagship product, the Quantra QPlus System. The Quantra System provides rapid, actionable coagulation results at the point of care – now viewable […]

Read More

Quality Assurance in Viscoelastic Testing – Reducing the QC Burden with the Quantra® System

How frequently do you have to run Quality Control (QC) on your viscoelastic testing (VET) device? What is the process for obtaining normal controls? How do you validate a new VET instrument for point-of-care use? These questions frequently arise when you are considering or evaluating a new VET point-of-care (POC) instrument. When it comes to […]

Read More

HemoSonics Registers CE Mark for its New QStat® Cartridge, Expanding the Use of its Innovative Quantra® Hemostasis System to Trauma Surgery and Liver Transplant Settings

Charlottesville, VA – September 10, 2019 – HemoSonics is excited to announce that its new QStat Cartridge, an extension of its groundbreaking Quantra Hemostasis System, has registered for CE Mark and is now commercially available in Europe and Hong Kong. The utility of the Quantra System, which was previously available with the QPlus® Cartridge for […]

Read More

FDA grants de novo for the HemoSonics’ Quantra® QPlus® System; This Revolutionary Diagnostic Provides Unique Information for Assessing Coagulation at the Point of Care; Now Commercially Available in US

Charlottesville, VA, January 19, 2021 – HemoSonics welcomes the January 14th guidance of the US Food and Drug Administration (FDA) that broadens the use of viscoelastic coagulation analyzers for hospital patient healthcare settings in response to COVID-19. The FDA guidance is intended, for the duration of the COVID-19 public health emergency, to expand the availability […]

Read More

Groundbreaking POC hemostasis diagnostic to be presented at Major European Meetings

Charlottesville, VA – May 24, 2018 – HemoSonics today announced it will be participating in the scientific proceedings as well as have a commercial presence at Euroanesthesia (ESA), to be held in Copenhagen, Denmark on June 2-4th. HemoSonics will be participating in the ESA’s pre-congress session on Point of Care Guided Haemostatic Management During Massive […]

Read More
1 2
Where We Will Be Next: